FDA approves new use of popular diabetes drug
The FDA approved Eli Lilly's Mounjaro to reduce major adverse cardiovascular event risks for high-risk adults with type 2 diabetes. While this expands the drug's clinical utility, Eli Lilly is now fighting a booming black market for retatrutide, an experimental injectable that outperformed previous obesity medications in clinical trials. This development occurs as GLP-1 use increases among U.S. children under 12 despite a lack of FDA approval. Access remains limited for some patients due to high costs and specific medical disqualifications within the Medicare Bridge pilot program.
What changed
Eli Lilly is combating a black market for retatrutide while GLP-1 use rises among children under 12 without FDA approval.
Live updates
-
FDA expands Mounjaro use as Eli Lilly battles black market for next obesity drug
The FDA approved Eli Lilly's Mounjaro to reduce major adverse cardiovascular event risks for high-risk adults with type 2 diabetes. While this expands the drug's clinical utility, Eli Lilly is now fighting a booming black market for retatrutide, an experimental injectable that outperformed previous obesity medications in clinical trials. This development occurs as GLP-1 use increases among U.S. children under 12 despite a lack of FDA approval. Access remains limited for some patients due to high costs and specific medical disqualifications within the Medicare Bridge pilot program.
Why it matters
GLP-1 drugs are becoming central to treating obesity and heart disease. Eli Lilly is leveraging these approvals to maintain coverage with insurers as some policies decline toward 2027. The emergence of next-generation drugs like retatrutide highlights the high demand and resulting illicit trade.
What is confirmed
- The FDA approved Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who face high risk.
- The Medicare Bridge pilot program excludes certain eligible individuals based on specific medical disqualifications.
Still unconfirmed
- A booming black market exists for the experimental drug retatrutide.
What to watch next
- FDA approval status for GLP-1 use in children under 12
- Clinical trial results and official FDA filing for retatrutide
- Changes to employer and insurer coverage for GLP-1 drugs leading into 2027
confidence 80%Sources used for this update (5)
- www.ibtimes.com.au — New Study Links Xylitol Sweetener To Higher Heart Attack And Stroke Risk In 17,700 People, Cardiologist Warns
- www.aol.com — GLP-1 use in US kids under-12 soars - even without FDA approval
- www.nola.com — Waiting for retatrutide: A ‘blockbuster’ new drug could help reduce Louisiana obesity rates
- www.ibj.com — Lilly fighting black market for its next obesity drug
- www.miamitimesonline.com — Top US doctors offer updated flu and COVID vaccine recommendations, aiming to ease confusion
-
FDA expands Mounjaro use for cardiovascular risk in type 2 diabetes
The FDA approved Eli Lilly's Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who face high risk for such events. This approval strengthens Eli Lilly's position in negotiations with employers and insurers as GLP-1 drug coverage declines toward 2027. While the drug's utility expands, patient access remains a hurdle; some patients cannot afford the monthly costs of related drugs like Zepbound, and the Medicare Bridge pilot program excludes certain eligible individuals based on specific medical disqualifications.
Why it matters
GLP-1 medications are increasingly used for both diabetes and weight loss. This specific approval shifts Mounjaro's clinical application toward preventative heart health. The timing is critical as healthcare payers tighten restrictions on these expensive therapies.
What is confirmed
- The FDA approved Mounjaro to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events.
- The Medicare Bridge pilot program excludes some individuals who would benefit from drugs such as Zepbound, Wegovy, and Ozempic.
Still unconfirmed
- Jeff La Marca was unable to afford a 750 dollar monthly price tag for Zepbound in January.
What to watch next
- Updates on Medicare Bridge pilot program eligibility criteria
- Changes in insurance coverage rates for GLP-1 drugs heading into 2027
confidence 90%Sources used for this update (8)
- tucson.com — Updated flu shots are available in Arizona. Should you get one now?
- www.texarkanagazette.com — The Medicare GLP-1 discount has one big catch: Some sick patients don't qualify
- www.rttnews.com — 6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More
- finance.yahoo.com — Medicare's $50 GLP-1 Bridge plan won't cover a morbidly obese NJ man because his sleep apnea disqualifies him
- www.prevention.com — COVID Cases Are Climbing Across the Country—Here Are the Top Symptoms to Expect in 2026
- muddyriversports.com — BloodPril Reviews 2026 – Legit Blood Pressure Support or Overhyped Supplement?
- www.statnews.com — Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorder
- www.el-balad.com — Leading U.S. groups issue Covid, Flu And Rsv Vaccine Recommendations
-
FDA Approves Mounjaro for Cardiovascular Risk Reduction in Type 2 Diabetes
The FDA has approved Eli Lilly's Mounjaro (tirzepatide) for a new use to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes. This expansion targets patients who are at high risk for cardiovascular events. The approval provides Eli Lilly with a strategic advantage in negotiations with insurers and employers at a time when coverage for GLP-1 drugs is declining heading into 2027.
Why it matters
Mounjaro belongs to a class of GLP-1 drugs used for diabetes and weight management. This new indication allows the drug to be marketed specifically for heart health rather than just glucose control. It positions Lilly against competitors like Novo Nordisk in the cardiovascular market.
What is confirmed
- The FDA approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes.
- Mounjaro is approved to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for CV events.
Still unconfirmed
- Employer coverage of GLP-1 drugs is collapsing heading into 2027.
- An Amgen drug could target a cardiovascular market that rivals the value of Eli Lilly's GLP-1 drugs.
What to watch next
- Changes in insurance coverage policies for GLP-1 drugs following the cardiovascular approval
- Clinical data or approval updates for Amgen's cardiovascular drug pipeline
confidence 100%Sources used for this update (11)
- Eli Lilly and Company — FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
- Fierce Pharma — Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients
- USA Today — Eli Lilly's diabetes drug Mounjaro gets approval for a new use
- Time Magazine — Mounjaro Is Now Approved to Lower the Risk of Heart Events
- Action News 5 — FDA approves new use of popular diabetes drug
- www.thecardiologyadvisor.com — Mounjaro Approved to Reduce MACE Risk in Adults With T2DM
- finance.yahoo.com — Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet
- finance.yahoo.com — Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance
- 247wallst.com — Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs
- www.aol.com — Yes, You Can Reverse Fatty Liver Disease—and Boost Weight Loss After 50
- uk.finance.yahoo.com — Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) Report Now Available — Delivers Pipeline Visibility and Deal-Grade Competitive Intelligence on 125 Companies Shaping ...